Clinical Trial Update: Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial comparing Rituximab to oral cyclophosphamide for eradicating or suppressing autoimmune anti-Factor VIII antibodies in acquired hemophilia A; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Hemophilia

Drugs mentioned

• Cyclophosphamide (oral) (Cyclophosphamide)
• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: Georgetown University | Conditions: Hemophilia A | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2017-02-10